English Overview
Dr. Said Khader discusses the once-a-week GLP-1 RA option Dulaglutide with a focus on the cardiovascular benefits of the therapy for T2DM patients.
This Activity for
- Resident / Fellow
- Physician
What I will learn?
To understand:
- Different cardiovascular trials design and patient population distribution
- The difference between primary and secondary CV protection
- Understand the results of recent CV trials for Dulaglutide and its implications on T2DM patients
- Different cardiovascular trials design and patient population distribution
- The difference between primary and secondary CV protection
- Understand the results of recent CV trials for Dulaglutide and its implications on T2DM patients
Speakers 1 Distinguished Speakers
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Once-a-Week GLP-1 RA: A Focus on CV Benefits Certificate
Certificate |
Certificate | Free |
VAT 15% Included
